CN113490422A - 用于抑制/减少体重增加的组合物 - Google Patents
用于抑制/减少体重增加的组合物 Download PDFInfo
- Publication number
- CN113490422A CN113490422A CN201980092530.4A CN201980092530A CN113490422A CN 113490422 A CN113490422 A CN 113490422A CN 201980092530 A CN201980092530 A CN 201980092530A CN 113490422 A CN113490422 A CN 113490422A
- Authority
- CN
- China
- Prior art keywords
- inhibiting
- composition
- weight gain
- reducing weight
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 235000019786 weight gain Nutrition 0.000 title claims abstract description 20
- 230000004584 weight gain Effects 0.000 title claims abstract description 18
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 25
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 23
- 241000282414 Homo sapiens Species 0.000 claims abstract description 12
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical class C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 23
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical group C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims description 21
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims description 19
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 17
- 235000013793 astaxanthin Nutrition 0.000 claims description 17
- 239000001168 astaxanthin Substances 0.000 claims description 17
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 17
- 229940022405 astaxanthin Drugs 0.000 claims description 17
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000037396 body weight Effects 0.000 description 19
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical class NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 5
- 241000168525 Haematococcus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 244000000231 Sesamum indicum Species 0.000 description 3
- 235000003434 Sesamum indicum Nutrition 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- -1 4-methyleneoxyphenyl Chemical group 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QUVCQYQEIOLHFZ-UHFFFAOYSA-N Seselin Chemical compound C1=CC(=O)OC2=C(C=CC(C)(C)O3)C3=CC=C21 QUVCQYQEIOLHFZ-UHFFFAOYSA-N 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- GNTBWYXKOMGRJX-UHFFFAOYSA-N 3,6-bis(3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan Chemical compound COC1=CC=CC(C2OCC3C(C4=CC(OC)=CC=C4)OCC23)=C1 GNTBWYXKOMGRJX-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000206486 Adonis Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241000131407 Brevundimonas Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 241001337904 Gordonia <angiosperm> Species 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 241001057811 Paracoccus <mealybug> Species 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000233671 Schizochytrium Species 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供一种用于抑制/减少体重增加的组合物。该用于抑制/减少体重增加的组合物具有优异的抑制或减少人体的体重增加的效果。该用于抑制/减少体重增加的组合物含有二氧杂双环[3.3.0]辛烷衍生物和抗氧化效价高于所述二氧杂双环[3.3.0]辛烷衍生物的抗氧化剂作为有效成分,且用于人体。
Description
技术领域
本发明涉及用于抑制或减少人体(人)的体重增加的体重增加抑制或减少用组合物。
背景技术
现代人由于运动不足和热量摄取过多,易于变胖,对于减肥、瘦身的需求大。为了可靠地进行瘦身或减肥,需要长时间地运动和限制热量。众所周知,例如禁食可以帮助您在最初几天减掉几公斤,但这并不是一种健康的方式。并且,减肥也可以通过限制热量来实现,但是要减掉几公斤需要一个多月的时间,还要忍受强烈的饥饿感,进而血糖不足,导致使用脑、骨骼肌的作业的品质、效率变差,因此难以继续进行。而且,在许多情况下,会反弹并恢复到原来的体重或增加体重。
因此,需要一种安全且对热量摄取没有限制的无需在健身房等进行任何特殊运动就可以在短短几周内对人体具有显著减肥效果的手段。据我们所知,迄今为止还没有发现这样科学可信的报告。
例如,降低体脂的异黄酮、抑制脂质和糖类吸收的膳食纤维、改善肠道菌群防止肥胖的乳酸菌、还有通过补充代谢酶预防肥胖的醋、刺激交感神经来促进脂肪分解的辣椒素等,以及其他在氨基酸、肽、低热量食物等中据说具有消除肥胖作用的产品。
另外,在专利文献1中,记载了与未给药的大鼠相比,口服芝麻素类导致生长中大鼠的体脂肪率表示的脂肪蓄积更少。然而,由于未显示标准偏差,并且芝麻素组的饲料食用量较少,因此尚不清楚是否由于芝麻素本身的影响。此外,仅提出了降低4周龄幼鼠体脂肪率的效果,尚未证实对成年鼠和老年鼠的影响。此外,在本实验中,芝麻素组的体重反而增加,并且没有描述显示人体体重减少的实验结果。
现有技术文献
专利文献
专利文献1:日本专利第3205315号
发明内容
发明要解决的课题
大量关于减肥的可疑宣传和报道正在泛滥,目前最受追捧的是科学可信的,而且有很多对老鼠有效但对人类无效,所以需要一种在短时间内对实际人类而非实验动物如小鼠实现显著瘦身和减肥效果的方法。
因此,本发明的目的在于提供一种抑制/减少体重增加的组合物,其具有优异的抑制/减少人体体重的效果。
用于解决课题的手段
本发明人通过对含有红球藻提取物和芝麻木酚素的食品进行安全性测试得到的数据进行分析,发现仅用2周时间,受试者的体重就显着减轻,从而完成了本发明。
即,本发明的用于抑制/减少体重增加用的组合物,其特征在于,含有作为有效成分的二氧杂双环[3.3.0]辛烷衍生物和具有比二氧杂双环[3.3.0]辛烷衍生物更高的抗氧化效价的抗氧化剂,用于人类。
本发明的用于抑制/减少体重增加用的组合物中,上述二氧杂双环[3.3.0]辛烷衍生物优选为芝麻素或表芝麻素。
此外,优选抗氧化剂效价高于二氧杂双环[3.3.0]辛烷衍生物的抗氧化剂是虾青素。
发明效果
二氧杂双环[3.3.0]辛烷衍生物(以下,有时简称为“DOBO衍生物”)很容易被氧化,在储存过程中如果存在氧气,会被氧化变质,因此被认为是由于体内活性氧而发生氧化变性。在本发明中,通过混合和配合比DOBO衍生物更容易氧化的抗氧化剂,DOBO衍生物可以在不变质的情况下被摄取到体内,并且对人类产生抑制/减少体重增加的优异效果。
具体实施方式
在本发明中,DOBO衍生物包括例如芝麻素、表芝麻素、芝麻素酚、表芝麻素酚、芝麻林素、2-(3,4-亚甲氧基苯基)-6-(3-甲氧基-4-羟基苯基)-3,7二氧杂双环[3.3.0]辛烷,2,6-双-(3甲氧基苯基)-3,7二氧杂双环[3.3.0]辛烷,2-(3,4-)亚甲二氧基苯基)-6-(3-甲氧基-4羟基苯氧基)-3,7二氧杂双环[3.3.0]辛烷等,在本发明中,可以使用这些中的一种或多种。这些化合物可以是糖苷的形式或者可以是光学活性的。
此外,作为DOBO衍生物,也可以使用从含有DOBO衍生物的原料中提取的提取物等。上述含有DOBO衍生物的原料包括,例如,芝麻油、芝麻酒糟、芝麻油制造过程的副产品、芝麻种子、刺五加皮、泡桐木、白果皮、长胡椒和姜。并且,从含有DOBO衍生物的原料中提取的提取物中DOBO衍生物的含量通常为0.1重量%以上,优选为1.0重量%以上,更优选为5.0重量%以上,特别地,芝麻素和表芝麻素的总含量优选为0.05重量%以上,优选为0.5重量%以上,更优选为2.0重量%以上。
并且,抗氧化效价高于DOBO衍生物的抗氧化剂包括,例如,虾青素、胡萝卜素、岩藻黄素、番茄红素、叶黄素、玉米黄质、抗坏血酸、生育酚等,在本发明中,可以使用这些中的一种或多种。特别优选使用虾青素。
本发明中可以使用的虾青素没有特别限制,可以使用天然虾青素和合成虾青素中的至少一种。天然虾青素包括从红球藻等藻类;fafia等酵母菌;虾、磷虾和螃蟹等贝类;鱿鱼和章鱼等头足类;各种海产品;adonis等植物;副球菌属N81106,短波单胞杆菌属SD212,赤细菌属PC6等细菌类;戈登氏菌属KANMONKAZ-1129等放线菌;海洋裂殖壶菌属KH105等盘蜷纲;产生虾青素的转基因生物;等中得到的虾青素,优选从微藻如红球藻中提取的虾青素,更优选从红球藻中提取的虾青素。并且,合成虾青素包括,例如,AstaSana(DSM)和Lucantin Pink(注册商标)(BASF)。此外,通过化学转化其他天然存在的类胡萝卜素获得的合成虾青素包括AstaMarine(PIVEG)。
在本发明中,抗氧化效价可以通过诸如ORAC(氧自由基吸收能力测定)或FRAP(铁还原抗氧化能力)等方法来测量。例如,作为DOBO衍生物之一的芝麻素的抗氧化效价为0.0012×109M-1s-1。此外,番茄红素是抗氧化效价高于DOBO衍生物的抗氧化剂之一,抗氧化效价为3.4×109M-1s-1,虾青素抗氧化效价为5.4×109M-1s-1。
本发明的用于抑制/减少体重增加的组合物的有效服用量为成人(初中生及以上)每天1~1000mg,优选10~500mg,更优选30~150mg,作为DOBO衍生物的服用量。此外,抗氧化效价高于OBO衍生物的抗氧化剂的服用量为成人(初中生及以上)每天0.005~500mg,优选0.002~10mg,更优选1.2~3mg。如果是小学生以下的儿童,则服用上述量的一半左右为宜。
本发明的用于抑制/减少体重增加的组合物的服用时间没有特别限定,但为了获得一定的效果,例如可以服用1周~12个月左右,优选0.1~3个月左右。此外,由于它不会引起任何副作用,因此可以服用更长的时间。
实施例
<测试例1>
制备根据本发明的用于抑制/减少体重增加的组合物的片剂,其包含下表1中所示的每粒复合组合物,并使用该片剂,根据下表2中所示的测试程序,让20岁~60岁的总共11名男性和女性每人每天服用5粒,进行体格检查的判定、理学检查及临床检查的判定。上述片剂中配合有芝麻素和虾青素。
测试由第三方的测试机关运营、管理,进行研究对象者的选择、检查结果的确认、统计以及统计分析。在一般的医疗机构进行了体格检查的判定、理学检查以及临床检查的判定、研究对象者的管理、研究实施体制的整备。
由于本测试是为了确认安全性而进行的,因此实验者和受试者完全没有意识到瘦身或减肥。如表2所示,受试者被要求过与日常生活相同的生活,并限制他们进行日常活动以外的新运动。
表3显示了体重和不良事件的结果数据。
[表1]
[表2]
[表3]
由表3可知,在服用目标食物第2周时,男性组体重和男女合计的总体体重与初检相比显着降低。由于本测试从一开始就不是减肥测试,样本数量是11个是合适的,但女性有性周期,比男性更容易便秘的女性也包括在受试者中,在第4周和服用结束后,男女合计的总体没有显著差异(P<0.05)。但显示了第4周和服用结束后的第2周的总体重为0.05<P<0.1,低于预先测量的体重。
这个结果的作用机制尚不清楚,但在常规实验中,芝麻素很容易被氧化,所以在短时间内使用人类的实验中,单独使用芝麻素似乎很难产生显著差异。这次实验之所以给出了明显的人体减肥效果,可能是因为虾青素比芝麻素具有更高的抗氧化能力,通过与芝麻素配合,虾青素在芝麻素被人体内的活性氧氧化之前被氧化,以防止芝麻素被氧化。作为一种可能的假设,DOBO衍生物如芝麻素作为解偶联剂可能通过产热促进基础代谢并减轻体重。表明为了充分发挥该DOBO衍生物的作用,需要混合配合比DOBO衍生物具有更大抗氧化能力的抗氧化剂。
<测试例2>
使用根据本发明的用于抑制/减少体重增加的组合物的片剂,其包含试验例1表1所示的每粒复合组合物,以12名成年男性(年龄在20岁以上64岁以下)为受试者,每天2粒或5粒,连续服用2周,研究对体重的影响。
结果,全部完成了预定的日程,并且预定的片剂摄入率为100%。表4和表5显示了测量每个受试者的体重并计算从服用开始的体重变化量的结果。表4表示每天服用2粒的受试者的结果,表5表示每天服用5粒的受试者的结果。
[表4]
体重测量结果(1天服用2粒:变化量)
*:p<0.05,**:p<0.03;(和初检比较,1标本t检定)
[表5]
体重测量结果(1天服用5粒:变化量)
*:p<0.05,**:p<0.03;(和初检比较,1标本t检定)
如上表4所示,在每天服用2粒的组中,与服用前相比,服用开始后的第1周和第2周的体重显著减轻。另外,服用结束后的第1周比服用结束时(开始服用后第2周)体重增加,但没有显着变化(p=0.40)。
如上表5所示,在每天服用5片的组中,服用开始1周后体重下降,但没有显着变化。另外,在第2周,与服用前相比,体重显着降低。此外,服用结束后的第1周比服用结束时(开始服用第2周)(开始摄入后的第2周)体重增加,但没有显着变化(p=0.78)。
根据以上结果,确定了根据本发明的用于抑制/减轻体重增加的组合物的上述片剂通过连续2周每天服用2或5粒而具有减轻体重的效果。
Claims (3)
1.一种用于抑制/减少体重增加的组合物,其特征在于,
含有二氧杂双环[3.3.0]辛烷衍生物和抗氧化效价高于所述二氧杂双环[3.3.0]辛烷衍生物的抗氧化剂作为有效成分,且所述用于抑制/减少体重增加的组合物用于人体。
2.根据权利要求1所述的用于抑制/减少体重增加的组合物,其特征在于,所述二氧杂双环[3.3.0]辛烷衍生物是芝麻素或表芝麻素。
3.根据权利要求1或2所述的用于抑制/减少体重增加的组合物,其特征在于,抗氧化效价高于所述二氧杂双环[3.3.0]辛烷衍生物的抗氧化剂是虾青素。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2019/007879 WO2020174669A1 (ja) | 2019-02-28 | 2019-02-28 | 体重増加抑制・低減用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113490422A true CN113490422A (zh) | 2021-10-08 |
Family
ID=72239175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980092530.4A Pending CN113490422A (zh) | 2019-02-28 | 2019-02-28 | 用于抑制/减少体重增加的组合物 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP7366991B2 (zh) |
CN (1) | CN113490422A (zh) |
TW (1) | TW202033190A (zh) |
WO (1) | WO2020174669A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04368326A (ja) * | 1991-06-15 | 1992-12-21 | Suntory Ltd | 新規組成物 |
US5270335A (en) * | 1990-10-22 | 1993-12-14 | Suntory Limited | Method of inhibiting metabolism of cholesterol |
US20070208077A1 (en) * | 2004-03-31 | 2007-09-06 | Yoshiko Ono | Adiponectin Enhancer |
JP2013126411A (ja) * | 2011-11-15 | 2013-06-27 | Kao Corp | ペットフード |
-
2019
- 2019-02-28 CN CN201980092530.4A patent/CN113490422A/zh active Pending
- 2019-02-28 WO PCT/JP2019/007879 patent/WO2020174669A1/ja active Application Filing
- 2019-02-28 JP JP2021501504A patent/JP7366991B2/ja active Active
- 2019-05-03 TW TW108115339A patent/TW202033190A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270335A (en) * | 1990-10-22 | 1993-12-14 | Suntory Limited | Method of inhibiting metabolism of cholesterol |
JPH04368326A (ja) * | 1991-06-15 | 1992-12-21 | Suntory Ltd | 新規組成物 |
US20070208077A1 (en) * | 2004-03-31 | 2007-09-06 | Yoshiko Ono | Adiponectin Enhancer |
JP2013126411A (ja) * | 2011-11-15 | 2013-06-27 | Kao Corp | ペットフード |
Non-Patent Citations (2)
Title |
---|
杨解人等: "芝麻素与维生素E联用对代谢综合征大鼠心肌损伤的协同保护作用", 《中药药理与临床》 * |
盛国华: "虾青素营养补充保健食品研究", 《中外食品》 * |
Also Published As
Publication number | Publication date |
---|---|
TW202033190A (zh) | 2020-09-16 |
JP7366991B2 (ja) | 2023-10-23 |
WO2020174669A1 (ja) | 2020-09-03 |
JPWO2020174669A1 (zh) | 2020-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brendler et al. | Astaxanthin: How much is too much? A safety review | |
Abdel-Daim | Pharmacodynamic interaction of Spirulina platensis with erythromycin in Egyptian Baladi bucks (Capra hircus) | |
CN102056499B (zh) | 用于调节脂质代谢的组合物 | |
Abdel-Tawwab | The use of American ginseng (Panax quinquefolium) in practical diets for Nile tilapia (Oreochromis niloticus): growth performance and challenge with Aeromonas hydrophila | |
US20210128664A1 (en) | Agent for Activating Astrocyte Glucose Metabolism | |
CN102784130A (zh) | 羟基酪醇用于改进线粒体功能的用途 | |
da Silva et al. | Essential oils of Ocimum gratissimum and Zingiber officinale as anesthetics for the South American catfish Pseudoplatystoma reticulatum | |
DE10109798A1 (de) | Gesundheitsfördernde Zusammensetzung von Verbindungen | |
Talbott et al. | Astaxanthin supplementation reduces depression and fatigue in healthy subjects | |
WO2021132077A1 (ja) | セサミン類及びpqqを含有する組成物 | |
Bhatia et al. | Amaranthus paniculatus (Linn.) improves learning after radiation stress | |
CN113490422A (zh) | 用于抑制/减少体重增加的组合物 | |
Wajizah et al. | Influence of syzygium cumini extract as feed additives on performance and haematological parameters of commercial broiler chickens | |
CN107372861B (zh) | 一种组合物及其在制备改善高血脂症的产品中的应用 | |
Balaji | Spirulina-small but a spectacular species | |
CN105709210A (zh) | 一种具有保护肝脏功能的保健食品 | |
ALTINTERİM et al. | Effect of macerated tomato (Lycopersicon esculentum) and carrot (Daucus carota) oils on hematological parameters of rainbow trout (Oncorhynchus mykiss) at high stocking density | |
Shahzadi et al. | M. Ilyas (2022). Anti-diabetic Effects of Aqueous plant (Citrullus colocynthis) Extract in Streptozotocin Induced Diabetic Mice | |
Aziz et al. | Combating Metabolic Syndrome through Non-Pharmacological Strategies: A Literature Review: Combating Metabolic Syndrome | |
WO2022071117A1 (ja) | 抗疲労用組成物及びエネルギー産生能の向上、低下抑制又は維持のための組成物 | |
Javid et al. | Effects of pomegranate juice with and without aerobic training on glycemic control and lipid profile in women with type 2 diabetes | |
Ojetayo et al. | Phytochemical Constituents of Cnestis ferruginea and Its Toxicity in Fish | |
Yakubu et al. | Antioxidant and protective properties of fish meal containing different inclusion levels of Sesame indicum (Beni seed) on acetaminophen-induxced oxidative stress in Clarias gariepinus | |
WO2024095303A1 (ja) | エネルギー産生の向上、低下抑制又は維持用組成物 | |
Ojetayo et al. | JURNAL PERIKANAN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211008 |
|
RJ01 | Rejection of invention patent application after publication |